SNY - European Drugmaker Sanofi Ends Tusamitamab Ravtansine Lung Cancer Program After Disappointing Data | Benzinga
Sanofi SA (NASDAQ: SNY) is discontinuing the global clinical development program of tusamitamab ravtansine.
The decision is based on the outcome of a prespecified interim analysis of Phase 3 CARMEN-LC03 trial evaluating tusamitamab ravtansine as monotherapy compared to docetaxel in previously treated patients with metastatic non-squamous non-small cell lung cancer whose tumors express high levels of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
An Independent Data Monitoring Committee found that tusamitamab ravtansine as monotherapy did ...